TradingKey

關於 Blueprint Medicines Corp 公司

Blueprint Medicines Corporation 是一家全球精準治療公司，正在過敏/炎症和腫瘤/血液學兩個領域發明改變生命的藥物。該公司向美國和歐洲的患者提供其獲批的藥物，包括 AYVAKIT/AYVAKYT (avapritinib) 和 GAVRETO (pralsetinib)，並在全球範圍內推進針對系統性肥大細胞增多症 (SM)、肺癌、乳腺癌和其他基因組定義的癌症以及癌症免疫療法的多個項目。該公司的產品線還包括 Elenestinib (BLU-263) (KIT)、AYVAKIT (avapritinib) (KIT)、野生型 KIT 研究項目、GAVRETO (pralsetinib) (RET)、BLU-945 (EGFR)、BLU-525 (EGFR)、BLU-451 (EGFR 外顯子 20 插入)、BLU-222 (CDK2)、AYVAKIT (PDGFRA)、GAVRETO (RET)、BLU-222 (CDK2) 和 BLU-852 (MAP4K1)。該公司正在開發一種口服、有效且高選擇性的試驗性 KIT 抑制劑 Elenestinib (BLU-263)，用於治療惰性 SM 和其他肥大細胞疾病。

公司簡介

公司代碼BPMC

公司名稱Blueprint Medicines Corp

上市日期Apr 30, 2015

成立日期2008

CEOMs. Kathryn D (Kate) Haviland

員工數量649

證券類型Ordinary Share

年結日Apr 30

公司地址45 Sidney Street

城市CAMBRIDGE

上市交易所NASDAQ Global Select Consolidated

國家United States of America

郵編02139

電話16173747580

網址https://www.blueprintmedicines.com/

公司代碼BPMC

上市日期Apr 30, 2015

成立日期2008

公司高階主管

名稱

名稱/職務

職務

持股

持股變動

Ms. Kathryn D (Kate) Haviland

President, Chief Executive Officer

73.23K

+22.22%

Ms. Debra Durso-Bumpus

Chief People Officer

44.19K

+15.24%

Dr. Fouad Namouni, M.D.

President - Research and Development

31.96K

+33.54%

Ms. Christina Rossi

Chief Operating Officer

19.39K

-19.00%

Mr. Percy H. Carter, Ph.D.

Chief Scientific Officer

16.43K

-13.93%

Mr. Michael Landsittel

Chief Financial Officer

13.43K

-68.90%

Ms. Ariel Hurley, CPA

Senior Vice President - Finance, Principal Accounting Officer

11.89K

--

Mr. Michael J. Tolpa

Director

--

Dr. Philina Lee, Ph.D.

Chief Commercial Officer

--

-100.00%

Ms. Jenna Cohen

Vice President and Head, Investor Relations

--

名稱

名稱/職務

職務

持股

持股變動

Ms. Kathryn D (Kate) Haviland

President, Chief Executive Officer

73.23K

+22.22%

Ms. Debra Durso-Bumpus

Chief People Officer

44.19K

+15.24%

Dr. Fouad Namouni, M.D.

President - Research and Development

31.96K

+33.54%

Ms. Christina Rossi

Chief Operating Officer

19.39K

-19.00%

Mr. Percy H. Carter, Ph.D.

Chief Scientific Officer

16.43K

-13.93%

Mr. Michael Landsittel

Chief Financial Officer

13.43K

-68.90%

收入明細

單位: USD更新時間: 4月6日週日

FY2024Q3

FY2024Q2

FY2024Q1

業務USD

名稱

營收

佔比

Product revenue

128.18M

100.00%

Collaboration, license and other revenue

1.00K

0.00%

地區USD

名稱

營收

佔比

United States

113.13M

88.26%

Rest of the world

15.05M

11.74%

業務

地區

業務USD

名稱

營收

佔比

Product revenue

128.18M

100.00%

Collaboration, license and other revenue

1.00K

0.00%

股東統計

更新時間: 7月30日週三

持股股東

股東類型

持股股東

佔比

The Vanguard Group, Inc.

10.25%

T. Rowe Price Associates, Inc.

8.28%

BlackRock Institutional Trust Company, N.A.

7.57%

Avoro Capital Advisors LLC

5.95%

Wellington Management Company, LLP

4.75%

Other

63.20%

持股股東

佔比

The Vanguard Group, Inc.

10.25%

T. Rowe Price Associates, Inc.

8.28%

BlackRock Institutional Trust Company, N.A.

7.57%

Avoro Capital Advisors LLC

5.95%

Wellington Management Company, LLP

4.75%

Other

63.20%

股東類型

持股股東

佔比

Investment Advisor

54.74%

Investment Advisor/Hedge Fund

39.84%

Hedge Fund

8.90%

Research Firm

2.98%

Sovereign Wealth Fund

1.10%

Individual Investor

0.93%

Venture Capital

0.77%

Bank and Trust

0.67%

Pension Fund

0.56%

機構持股

更新時間: 7月1日週二

報告期間

機構數

持股數

持股佔比

持股變動

2025Q2

695

70.23M

108.61%

-1.76M

2025Q1

702

71.75M

110.98%

-1.27M

2024Q4

657

69.17M

108.25%

-2.83M

2024Q3

644

67.12M

105.97%

-7.85M

2024Q2

622

68.23M

108.95%

-6.94M

2024Q1

615

67.81M

110.73%

-5.62M

2023Q4

612

65.87M

108.35%

-10.02M

2023Q3

602

66.47M

109.56%

-7.64M

2023Q2

614

65.78M

108.78%

-8.60M

2023Q1

625

65.63M

109.42%

-10.28M

股東持股明細

名稱

持股數

佔比

持股變動

變動比例

公告日期

The Vanguard Group, Inc.

6.63M

10.25%

-134.36K

-1.99%

Mar 31, 2025

T. Rowe Price Associates, Inc.

5.35M

8.28%

-266.46K

-4.74%

Mar 31, 2025

BlackRock Institutional Trust Company, N.A.

4.89M

7.57%

-106.17K

-2.12%

Mar 31, 2025

Avoro Capital Advisors LLC

3.85M

5.95%

+2.67M

+224.89%

Mar 31, 2025

Wellington Management Company, LLP

3.07M

4.75%

-1.21M

-28.22%

Mar 31, 2025

State Street Global Advisors (US)

2.68M

4.15%

+183.91K

+7.36%

Mar 31, 2025

JP Morgan Asset Management

2.03M

3.15%

+1.33M

+187.97%

Mar 31, 2025

Geode Capital Management, L.L.C.

1.52M

2.35%

+32.55K

+2.18%

Mar 31, 2025

T. Rowe Price Investment Management, Inc.

1.30M

2.01%

+605.78K

+86.91%

Mar 31, 2025

Macquarie Investment Management

1.29M

1.99%

+27.92K

+2.22%

Mar 31, 2025

持股ETF

更新時間: 7月6日週日

機構名稱

佔比

Invesco Biotechnology & Genome ETF

3.22%

Tema Oncology ETF

2.73%

SPDR S&P Biotech ETF

2.04%

Motley Fool Small-Cap Growth ETF

1.6%

Direxion Daily S&P Biotech Bull 3X Shares

1.47%

American Century Focused Dynamic Growth ETF

1.32%

JPMorgan Fundamental Data Science Small Core ETF

1.1%

ProShares Ultra Nasdaq Biotechnology

0.94%

Hypatia Women CEO ETF

0.8%

Invesco Nasdaq Biotechnology ETF

0.73%

Invesco Biotechnology & Genome ETF

佔比3.22%

Tema Oncology ETF

佔比2.73%

SPDR S&P Biotech ETF

佔比2.04%

Motley Fool Small-Cap Growth ETF

佔比1.6%

Direxion Daily S&P Biotech Bull 3X Shares

佔比1.47%

American Century Focused Dynamic Growth ETF

佔比1.32%

JPMorgan Fundamental Data Science Small Core ETF

佔比1.1%

ProShares Ultra Nasdaq Biotechnology

佔比0.94%

Hypatia Women CEO ETF

佔比0.8%

Invesco Nasdaq Biotechnology ETF

佔比0.73%

分紅派息

近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股

公告日期

類型

比率

暫無數據

公告日期

類型

比率

暫無數據

Blueprint Medicines Corp

129.460USD

Blueprint Medicines Corp

129.460

概覽

公司

財務